EUVIMEDEUVIMED entdecken
Crossref

Antitumor Activity of a Bispecific Chimera Targeting EGFR and Met in Gefitinib‐Resistant Non‐Small Cell Lung Cancer

Ya Wang, Guixi Zhang, Zhilan Zhou, Ning Zhang, Hang Jiang, Yichang Liu, Ting Fu, Yingdi Zhu, Juan Li iD

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202402884 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Ya Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Materials, University of Science and Technology of China, Hefei, 230026, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Gefitinib, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Zhejiang Leading Innovation and Entrepreneurship Team.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non‐small cell lung cancers (NSCLC) frequently acquire resistance to tyrosine kinase inhibitors (TKI) due to epidermal growth factor receptor (EGFR) mutation or activation of the bypass pathway involving mesenchymal‐epithelial transition factor (Met). To address this challenge, a bispecific nanobody‐aptamer chimera is designed to target mutated EGFR and Met simultaneously to block their cross‐talk in NSCLC. The EGFR‐Met chimera is cost‐effectively engineered using microbial transglutaminase and click chemistry strategies. With enhanced binding affinity toward the target proteins, the as‐developed chimera inhibits efficiently the cross‐talk between signaling pathways associated with EGFR and Met. This inhibition leads to the suppression of downstream pathways, such as Erk and Akt, and induces upregulation of cell cycle arrest‐related proteins, including Rb, p21, and p27. Additionally, the chimera activates the caspase‐dependent apoptotic signaling pathway. Consequently, it inhibits cell migration, induces cell death, and causes cell cycle arrest in vitro. Moreover, the chimera exhibits significant antitumor efficacy in drug‐resistant xenograft mouse models, showcasing improved tissue penetration and low toxicity. This study accentuates the potential of the bispecific EGFR‐Met chimera as a promising therapeutic option for NSCLC resistant to EGFR TKIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErbB ReceptorsGefitinibLung NeoplasmsProto-Oncogene Proteins c-metDrug Resistance, NeoplasmAntineoplastic AgentsAntibodies, BispecificHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysMice, NudeApoptosisMice, Inbred BALB CProtein Kinase InhibitorsSignal Transduction

Stichwörter der Autor:innen

EGFR mutationsMet overexpressionaptamersbispecific chimeradrug resistance

Substanzen

ErbB ReceptorsGefitinibProto-Oncogene Proteins c-metEGFR protein, humanAntineoplastic AgentsMET protein, humanAntibodies, BispecificProtein Kinase Inhibitors

Autor:innen und Institutionen

  • School of Chemistry and Materials, University of Science and Technology of China, Hefei, 230026, China.
  • Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.
  • School of Pharmacy, Nantong University, Nantong, 226019, China.

ORCID-Profile: Juan Li

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Zhejiang Leading Innovation and Entrepreneurship Team
  • Pioneer R&D Program of Zhejiang

Zitieren

APA

Wang, Y., Zhang, G., Zhou, Z., Zhang, N., Jiang, H., Liu, Y., Fu, T., Zhu, Y., & Li, J. (2025). Antitumor Activity of a Bispecific Chimera Targeting EGFR and Met in Gefitinib‐Resistant Non‐Small Cell Lung Cancer. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202402884

Vancouver

Wang Y, Zhang G, Zhou Z, Zhang N, Jiang H, Liu Y, et al. Antitumor Activity of a Bispecific Chimera Targeting EGFR and Met in Gefitinib‐Resistant Non‐Small Cell Lung Cancer. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202402884

BibTeX
@article{Wang2025,
  author = {Wang, Ya and Zhang, Guixi and Zhou, Zhilan and Zhang, Ning and Jiang, Hang and Liu, Yichang and Fu, Ting and Zhu, Yingdi and Li, Juan},
  title = {Antitumor Activity of a Bispecific Chimera Targeting EGFR and Met in Gefitinib‐Resistant Non‐Small Cell Lung Cancer},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202402884}
}
Kostenlos starten →